Dr Kevin Kalinsky talks to ecancer about his postMONARCH trial.

The Phase 3 postMONARCH trial evaluated abemaciclib plus fulvestrant versus placebo plus fulvestrant in HR+, HER2- advanced breast cancer patients who progressed on prior CDK4/6 inhibitor and endocrine therapy.

The study showed that abemaciclib significantly improved progression-free survival with a hazard ratio of 0.73 and a 6-month PFS rate of 50% compared to 37% with placebo.

Objective response rate was also higher with abemaciclib (17% vs. 7%), and safety was consistent with known profiles of the drug.

Overall survival data is still immature.